Trials / Completed
CompletedNCT03387215
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Intra-Cellular Therapies, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITI-214 | Oral |
| OTHER | Placebo | Oral |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
- First posted
- 2018-01-02
- Last updated
- 2020-12-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03387215. Inclusion in this directory is not an endorsement.